BioAge Launches Phase 2 Trial Testing Inflammaging Drug for Cardiovascular Risk
BioAge's BGE-102 targets the NLRP3 inflammasome to reduce chronic inflammation linked to aging and heart disease — Phase 2 now underway.
Summary
BioAge Labs has dosed the first participant in QUELL-CV, a Phase 2 trial testing BGE-102, an oral drug that blocks the NLRP3 inflammasome — a key driver of chronic low-grade inflammation linked to aging. Unlike most drug programs, BioAge discovered this target by analyzing human longevity datasets, identifying what separates people who age well from those who don't. The trial uses high-sensitivity C-reactive protein (hsCRP) as its primary biomarker to measure anti-inflammatory effects and establish dosing, with a focus on adults carrying elevated cardiovascular risk. If successful, this approach could validate inflammaging as a druggable target across multiple age-related diseases, not just heart disease — a potential milestone for longevity medicine.
Detailed Summary
Chronic low-grade inflammation — dubbed inflammaging — has emerged as one of the most consistent threads running through aging biology. It appears in cardiovascular disease, neurodegeneration, and metabolic decline, yet no drug has convincingly shown it can be targeted to slow aging itself. BioAge Labs is now attempting to change that with BGE-102, an oral NLRP3 inflammasome inhibitor entering Phase 2 clinical testing.
The QUELL-CV trial has enrolled its first participant, marking a meaningful step forward. The randomized proof-of-concept study focuses on adults with elevated systemic inflammation and heightened cardiovascular risk. Rather than measuring heart attacks or strokes directly, the trial tracks high-sensitivity C-reactive protein (hsCRP) as its primary endpoint — a well-established inflammatory biomarker — alongside a broader panel of cardiometabolic markers to guide potential Phase 3 development.
What distinguishes BGE-102 is how it was discovered. Most drugs begin with a disease and trace backward to a biological target, a process that frequently fails when animal data doesn't translate to humans. BioAge reversed this approach: its platform analyzed large datasets from aging cohorts, comparing people who remain healthy into old age with those who don't, then identified which biological pathways differed most. NLRP3 emerged from that human-first analysis — meaning it was validated in the context of aging before being mapped onto any specific disease.
This matters because if the same mechanism proves beneficial across cardiovascular disease, neurodegeneration, and other age-related conditions, it would suggest researchers are genuinely targeting shared aging biology rather than isolated pathologies — a long-standing goal in geroscience.
The key caveat is that reducing hsCRP is a surrogate endpoint, not a direct measure of healthspan or lifespan. Biomarker improvements don't automatically translate into clinical benefit. Phase 3 trials powered for hard outcomes would be needed to confirm real-world impact. Still, QUELL-CV represents one of the most mechanistically grounded attempts yet to turn inflammaging into a prescribable medicine.
Key Findings
- BGE-102 is a once-daily oral NLRP3 inhibitor now in Phase 2 testing for cardiovascular inflammatory risk in older adults.
- The QUELL-CV trial uses hsCRP reduction as its primary endpoint to establish dose-response relationships before Phase 3.
- BioAge discovered the NLRP3 target through human longevity datasets — not conventional disease models — improving translational odds.
- If effective across conditions, BGE-102 could validate inflammaging as a shared, druggable aging mechanism beyond heart disease.
- Human-first drug discovery may reduce the high failure rate seen when animal-derived targets are tested in people.
Methodology
This is a news report from Longevity.Technology summarizing a clinical trial announcement and CEO interview. The source is a credible longevity-focused outlet; the trial is a registered Phase 2 randomized study. Evidence is early-stage clinical, not yet peer-reviewed outcome data.
Study Limitations
hsCRP is a surrogate biomarker — trial results will not directly confirm improved healthspan or reduced disease events. The article draws on a CEO interview, which may reflect optimistic framing. Phase 3 trials with hard clinical endpoints are required before any clinical recommendations can be made.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: